CA2533587A1 — Compounds active in sphingosine 1-phosphate signaling

USPTO Abstract

The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure of Formula (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is selected from the group consisting of C3-C6 optionally substituted cycloalkyl, C3-C6 optionally substituted heterocyclic, C3-C6 optionally substituted aryl C3-C6 optionally substituted heteroaryl and -NH(CO)-; R2 is selected from the group consisting of H, C1 -C4 alkyl, (C1 -C4 alkyl)OH and (C1-C4 alkyl)NH2; R23 is H or C1-C4 alkyl, and R15 is selected from the group consisting of hydroxy, phosphonate, and of Formula (II) wherein X and R12 is selected from the group consisting of O and S; or a pharmaceutically acceptable salt or tautomer thereof.